Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy

References

• Ganan-Gomez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015;29(7):1458–12. doi:10.1038/leu.2015.69.
   PubMed Web of Science ®Google Scholar
• Weber S, Parmon A, Kurrle N, Schnutgen F, Serve H. The clinical significance of iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia. Front Immunol. 2021;11:627662. doi:10.3389/fimmu.2020.627662.
   PubMed Web of Science ®Google Scholar
• Zanetti C, Krause DS. “Caught in the net”: the extracellular matrix of the bone marrow in normal hematopoiesis and leukemia. Exp Hematol. 2020;89:13–25. doi:10.1016/j.exphem.2020.07.010.
   PubMed Web of Science ®Google Scholar
• Frevert CW, Felgenhauer J, Wygrecka M, Nastase MV, Schaefer L. Danger-associated molecular patterns derived from the extracellular matrix provide temporal control of innate immunity. J Histochem Cytochem. 2018;66(4):213–227. doi:10.1369/0022155417740880.
   PubMed Web of Science ®Google Scholar
• Roedig H, Damiescu R, Zeng-Brouwers J, Kutija I, Trebicka J, Wygrecka M, Schaefer L. Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development. Semin Cancer Biol. 2020;62:31–47. doi:10.1016/j.semcancer.2019.07.026.
   PubMed Web of Science ®Google Scholar
• Appunni S, Rubens M, Ramamoorthy V, Anand V, Khandelwal M, Sharma A. Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol Cell Biochem. 2021;476(11):3935–3950. doi:10.1007/s11010-021-04216-z.
   PubMed Web of Science ®Google Scholar
• Miguez PA. Evidence of biglycan structure-function in bone homeostasis and aging. Connect Tissue Res. 2020;61(1):19–33. doi:10.1080/03008207.2019.1669577.
   PubMed Web of Science ®Google Scholar
• Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Gröne H-J, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. 2009;284(36):24035–24048. doi:10.1074/jbc.M109.014266.
   PubMed Web of Science ®Google Scholar
• Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280(10):2165–2179. doi:10.1111/febs.12145.
   PubMed Web of Science ®Google Scholar
• Roedig H, Nastase MV, Wygrecka M, Schaefer L. Breaking down chronic inflammatory diseases: the role of biglycan in promoting a switch between inflammation and autophagy. FEBS J. 2019;286(15):2965–2979. doi:10.1111/febs.14791.
   PubMed Web of Science ®Google Scholar
• Diehl V, Huber LS, Trebicka J, Wygrecka M, Iozzo RV, Schaefer L. The role of decorin and biglycan signaling in tumorigenesis. Front Oncol. 2021;11:801801. doi:10.3389/fonc.2021.801801.
   PubMed Web of Science ®Google Scholar
• Zeng-Brouwers J, Pandey S, Trebicka J, Wygrecka M, Schaefer L. Communications via the small leucine-rich proteoglycans: molecular specificity in inflammation and autoimmune diseases. J Histochem Cytochem. 2020;68(12):887–906. doi:10.1369/0022155420930303.
   PubMed Web of Science ®Google Scholar
• Niedworok C, Rock K, Kretschmer I, Freudenberger T, Nagy N, Szarvas T, Vom Dorp F, Reis H, Rübben H, Fischer JW, et al. Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer. PLoS One. 2013;8(11):e80084. doi:10.1371/journal.pone.0080084.
   PubMed Web of Science ®Google Scholar
• Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G, Gress TM. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 2001;121(3):657–667. doi:10.1053/gast.2001.27222.
   PubMed Web of Science ®Google Scholar
• Zhao SF, Yin XJ, Zhao WJ, Liu LC, Wang ZP. Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers. Oncol Lett. 2020;19:1673–1682.
   PubMed Web of Science ®Google Scholar
• Subbarayan K, Leisz S, Wickenhauser C, Bethmann D, Massa C, Steven A, Seliger B. Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. Oncoimmunology. 2018;7(4):e1373233. doi:10.1080/2162402X.2017.1373233.
   PubMed Web of Science ®Google Scholar
• Wagner W, Saffrich R, Wirkner U, Eckstein V, Blake J, Ansorge A, Schwager C, Wein F, Miesala K, Ansorge W, et al. Hematopoietic progenitor cells and cellular microenvironment: behavioral and molecular changes upon interaction. Stem Cells. 2005;23(8):1180–1191. doi:10.1634/stemcells.2004-0361.
   PubMed Web of Science ®Google Scholar
• Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–1048. doi:10.1182/blood-2018-10-844654.
   PubMed Web of Science ®Google Scholar
• Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960–2975. doi:10.1182/blood-2016-07-730556.
   PubMed Web of Science ®Google Scholar
• Banerjee T, Calvi LM, Becker MW, Liesveld JL. Flaming and fanning: the spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019;36:57–69. doi:10.1016/j.blre.2019.04.004.
   PubMed Web of Science ®Google Scholar
• Campo S, Campo GM, Avenoso A, D’Ascola A, Musolino C, Calabro L, Bellomo G, Quartarone E, Calatroni A. Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin. Biochimie. 2006;88(12):1933–1939. doi:10.1016/j.biochi.2006.07.010.
   PubMed Web of Science ®Google Scholar
• Rydstrom K, Joost P, Ehinger M, Eden P, Jerkeman M, Cavallin-Stahl E, Linderoth J. Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(9):1764–1768. doi:10.3109/10428194.2012.666541.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liang S, Zhan Q, Yang L, Chi J, Wang L. HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia. Cell Death Dis. 2020;11(6):492. doi:10.1038/s41419-020-2694-7.
   PubMed Web of Science ®Google Scholar
• Bauer M, Vaxevanis C, Bethmann D, Massa C, Pazaitis N, Wickenhauser C, Seliger B, et al. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. Methods Enzymol. 2020;635:67–79.
   PubMed Web of Science ®Google Scholar
• Bauer M, Vaxevanis C, Al-Ali HK, Jaekel N, Naumann CLH, Schaffrath J, Rau A, Seliger B, Wickenhauser C. Altered spatial composition of the immune cell repertoire in association to CD34+ blasts in myelodysplastic syndromes and secondary acute myeloid leukemia. Cancers. 2021;13(2):186. doi:10.3390/cancers13020186.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Vaxevanis CK, Biehl K, Mueller A, Seliger B. Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744. J Immunother Cancer. 2020;8(1):e000396. doi:10.1136/jitc-2019-000396.
   PubMed Web of Science ®Google Scholar
• Chen J, Kao Y-R, Sun D, Todorova TI, Reynolds D, Narayanagari S-R, Montagna C, Will B, Verma A, Steidl U, et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med. 2019;25(1):103–110. doi:10.1038/s41591-018-0267-4.
   PubMed Web of Science ®Google Scholar
• Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129(12):1586–1594. doi:10.1182/blood-2016-10-696062.
   PubMed Web of Science ®Google Scholar
• Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M, et al. The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115(8):2223–2233. doi:10.1172/JCI23755.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Shi L, Zhao Y, Fei C, Guo J, Jia Y, Wu D, Wu L, Chang C. Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation. Aging. 2019;11(21):9626–9642. doi:10.18632/aging.102409.
   PubMedGoogle Scholar
• He X, Wang H, Jin T, Xu Y, Mei L, Yang J, Beltrami AP. TLR4 activation promotes bone marrow MSC proliferation and osteogenic differentiation via Wnt3a and Wnt5a signaling. PLoS One. 2016;11(3):e0149876. doi:10.1371/journal.pone.0149876.
   PubMed Web of Science ®Google Scholar
• Recher C. Clinical implications of inflammation in acute myeloid leukemia. Front Oncol. 2021;11:623952. doi:10.3389/fonc.2021.623952.
   PubMed Web of Science ®Google Scholar
• Heegaard AM, Xie Z, Young MF, Nielsen KL. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors. J Cell Biochem. 2004;93(3):463–475. doi:10.1002/jcb.20189.
   PubMed Web of Science ®Google Scholar
• Maishi N, Ohba Y, Akiyama K, Ohga N, Hamada J, Nagao-Kitamoto H, Alam MT, Yamamoto K, Kawamoto T, Inoue N, et al. Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Sci Rep. 2016;6(1):28039. doi:10.1038/srep28039.
   PubMedGoogle Scholar
• Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, Schaefer L, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 2010;120(12):4251–4272. doi:10.1172/JCI42213.
   PubMed Web of Science ®Google Scholar
• Tzanakakis G, Neagu M, Tsatsakis A, Nikitovic D. Proteoglycans and immunobiology of cancer—therapeutic implications. Front Immunol. 2019;10:875. doi:10.3389/fimmu.2019.00875.
   PubMed Web of Science ®Google Scholar
• Mailer RK, Joly AL, Liu S, Elias S, Tegner J, Andersson J. IL-1beta promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep. 2015;5:14674. doi:10.1038/srep14674.
   PubMed Web of Science ®Google Scholar